Multispecific binding proteins for cancer treatment
By designing a multispecific binding protein that simultaneously binds CD3 on T cells and B7H6 on tumor cells, the problem of low efficiency and short half-life of existing B7H6-targeted therapies has been solved, achieving highly efficient treatment of B7H6-expressing tumors, especially improved treatment effects for cancers such as colorectal cancer.
Patent Information
- Application Number
- CN202511886140.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2019-10-02
- Filing Date
- 2020-10-01
- Publication Date
- 2026-05-29
AI Technical Summary
Existing B7H6-targeted therapies such as ADCC/CDC have low activity, ADC methods have limitations and off-target toxicity, and CAR-T cells and T cell adaptor antibodies have short half-lives, making them unable to effectively treat tumors expressing B7H6, especially colorectal cancer and other cancers.
A bispecific T-cell binding method was developed, which uses a multispecific binding protein to simultaneously bind CD3 on T cells and B7H6 on tumor cells, promoting the formation of cell lysis synapses between T cells and tumor cells, thereby achieving selective targeted killing of tumor cells.
It improves therapeutic efficacy, reduces side effects, prolongs half-life, reduces immunogenicity, reduces the number of administrations, provides an improved therapeutic window and lower dose requirements, and is adapted to more effective cancer treatment.